



Enzon Pharmaceuticals Inc.  
Investor Relations Department  
20 Kingsbridge Road  
Attn: Accounts Payable  
Piscataway, NJ 08854  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### OT: ENZN <sup>1</sup>


Last Trade:	0.30
Trade Time:	3:50 PM ET Oct 20, 2017
Change:	0.01  (4.138%)
Day Range	0.29 - 0.30
52-Week Range	0.03 - 0.50
Volume	62,257
Market Cap. (\$M)	13.354
Shares Out (M)	44.220

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron <sup>®</sup>, Sylatron <sup>®</sup>, Macugen <sup>®</sup> and CIMZIA <sup>®</sup>. ... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

May 1, 2014

[Enzon Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards](#)

Apr 23, 2013

[Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces \\$1.60 Special Dividend and Periodic Royalty Dividends](#)

Mar 18, 2013

[Enzon Reports Fourth Quarter and Full Year 2012 Results](#)

Dec 17, 2012

[Enzon to Review Asset Sales, Sale of the Company](#)

Nov 29, 2012

[Enzon Announces Special Dividend](#)

### Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

### Financials [\[ View all \]](#)

Mar 24, 2017

[Annual Report \(10-K\)](#)

May 12, 2017

[Definitive Proxy Statement](#)

Aug 10, 2017

[Quarterly Report \(10-Q\)](#)

May 11, 2017

[Quarterly Report \(10-Q\)](#)

Nov 10, 2016

[Quarterly Report \(10-Q\)](#)